Fungal Update: Mycology 2024 is a two-day conference which brings together the fungal community to discuss the latest updates in the world of medical mycology.

Abstract. In this multicenter study of 387 immunocompromised patients, 4.5% with invasive pulmonary aspergillosis (IPA) also had Pneumocystis jirovecii pne

Rezafungin is a second-generation echinocandin that has shown activity against a range of Candida species including wild-type and azole- and echinocandin-resistant isolates (1–3). Rezafungin has improved chemical and biological properties that are distinct from other echinocandins. Most notably, the modified backbone of rezafungin leads to a stable chemical structure with reduced metabolism and degradation relative to other echinocandins. This results in a longer half-life, which allows for weekly dosing, improved tissue penetration, and reduced organ toxicity (4, 5). Less frequent dosing also results in high front-loaded exposure, which, along with good distribution to and penetration at infection sites may allow earlier mycological clearance from sites of infection with the potential to prevent the emergence of resistance (4, 6–10). Rezafungin was approved in 2023 by the United States Food and Drug Administration for the treatment of candidemia and invasive candidiasis based on clinical efficacy and safety data from the randomized Phase 2 STRIVE and Phase 3 ReSTORE clinical trials (10–12).

Alt: Tobias Fünke standing if front of a crowd in a brown suit, yelling "There are dozens of us. DOZENS!" while pointing to the sky